A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Study Purpose

The purpose of this study is to describe the use of teclistamab in the treatment of patients with RRMM outside of clinical trials.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Have a documented diagnosis of multiple myeloma.
  • - Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment.
  • - Received at least one dose of teclistamab.
  • - Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements.

Exclusion Criteria:

- Received teclistamab as part of an interventional clinical trial

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06285318
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Janssen-Cilag Ltd.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Janssen-Cilag Limited Clinical Trial
Principal Investigator Affiliation Janssen-Cilag Limited
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Denmark, France, Germany, Israel, Italy, Spain, Sweden
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Relapsed/Refractory Multiple Myeloma (RRMM)
Arms & Interventions

Arms

: Participants with Relapsed/Refractory Multiple Myeloma (RRMM)

Participants with RRMM who received at least one dose of teclistamab outside of clinical trials on or before 31 December 2022 will be enrolled in the study. The data available from the medical records of each enrolled participant will be the collected to describe the use of teclistamab.

Interventions

Other: - teclistamab

No Intervention will be administered during the study. Retrospective data analysis using participants medical records data collected within this study will be entered into Case Report Form (CRF).

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Rigshospitalet, Copenhagen, Denmark

Status

Recruiting

Address

Rigshospitalet

Copenhagen, , 2100

Odense University Hospital, Odense, Denmark

Status

Recruiting

Address

Odense University Hospital

Odense, , 5000

Sygehus Lillebælt, Vejle, Vejle, Denmark

Status

Recruiting

Address

Sygehus Lillebælt, Vejle

Vejle, , 7100

Hopital Albert Calmette - CHU Lille, Lille cedex, France

Status

Recruiting

Address

Hopital Albert Calmette - CHU Lille

Lille cedex, , 59037

Institut Paoli Calmettes, Marseille, France

Status

Recruiting

Address

Institut Paoli Calmettes

Marseille, , 13009

Hopital Saint Louis, Paris, France

Status

Recruiting

Address

Hopital Saint Louis

Paris, , 75475

Toulouse Cedex 9, France

Status

Recruiting

Address

Institut Universitaire du Cancer Toulouse Oncopole

Toulouse Cedex 9, , 31100

Wurzburg, Germany

Status

Recruiting

Address

Universitätsklinikum Würzburg Med. Klinik U. Poliklinik Ii

Wurzburg, , 97080

Sheba Medical Center, Ramat Gan, Israel

Status

Recruiting

Address

Sheba Medical Center

Ramat Gan, , 52621

Tel Aviv Sourasky Medical Center, Tel Aviv Yafo, Israel

Status

Recruiting

Address

Tel Aviv Sourasky Medical Center

Tel Aviv Yafo, , 6423906

Policlinico Sant'Orsola Malpighi, Bologna, Italy

Status

Recruiting

Address

Policlinico Sant'Orsola Malpighi

Bologna, , 40138

Policlinico di Milano, Milano, Italy

Status

Recruiting

Address

Policlinico di Milano

Milano, , 20121

Roma, Italy

Status

Recruiting

Address

Presidio Ospedaliero Santo Spirito in Sassia

Roma, , 65124

Hosp. Univ. de La Paz, Madrid, Spain

Status

Recruiting

Address

Hosp. Univ. de La Paz

Madrid, , 28046

Hosp. Costa Del Sol, Malaga, Spain

Status

Recruiting

Address

Hosp. Costa Del Sol

Malaga, , 29603

Länssjukhuset Ryhov, Jonkoping, Sweden

Status

Recruiting

Address

Länssjukhuset Ryhov

Jonkoping, , 551 85